{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T15:00:37Z","timestamp":1767193237647,"version":"3.37.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Hangzhou biomedicine and health industry development project","award":["2023WJC171","No. 2021WJCY320"],"award-info":[{"award-number":["2023WJC171","No. 2021WJCY320"]}]},{"name":"Hangzhou Medical and Health Science and Technology Project","award":["ZD20220049","Z20220017","A20210199","A20220780"],"award-info":[{"award-number":["ZD20220049","Z20220017","A20210199","A20220780"]}]},{"name":"Zhejiang Medical and Health Science and Technology Project","award":["2021KY910"],"award-info":[{"award-number":["2021KY910"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00228-024-03788-1","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T16:20:32Z","timestamp":1736353232000},"page":"347-363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Population pharmacokinetics of bedaquiline: a systematic review"],"prefix":"10.1007","volume":"81","author":[{"given":"Jie","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lifang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinjun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinmeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"3788_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1146\/annurev.publhealth.23.100901.140519","volume":"23","author":"P Tiruviluamala","year":"2002","unstructured":"Tiruviluamala P, Reichman LB (2002) Tuberculosis. Annu Rev Public Health 23:403\u2013426","journal-title":"Annu Rev Public Health"},{"key":"3788_CR2","doi-asserted-by":"publisher","DOI":"10.30875\/9789287074287","volume-title":"WHO report 2023: global tuberculosis control","author":"World Health Organization","year":"2023","unstructured":"World Health Organization (2023) WHO report 2023: global tuberculosis control. WHO, Geneva Switzerland"},{"issue":"2","key":"3788_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2471\/BLT.11.092585","volume":"90","author":"M Zignol","year":"2012","unstructured":"Zignol M, van Gemert W, Falzon D et al (2012) Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007\u20132010. Bull World Health Organ 90(2):111-119D. https:\/\/doi.org\/10.2471\/BLT.11.092585","journal-title":"Bull World Health Organ"},{"issue":"8","key":"3788_CR4","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3201\/eid2108.141860","volume":"21","author":"CC Dobler","year":"2015","unstructured":"Dobler CC, Korver S, Batbayar O et al (2015) Multidrug-Resistant Tuberculosis in Patients for Whom First-Line Treatment Failed, Mongolia, 2010\u20132011. Emerg Infect Dis 21(8):1451\u20131454. https:\/\/doi.org\/10.3201\/eid2108.141860","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"3788_CR5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.5582\/ddt.2015.01012","volume":"9","author":"R Prasad","year":"2015","unstructured":"Prasad R, Gupta N, Balasubramanian V et al (2015) Multidrug resistant tuberculosis treatment in India. Drug Discov Ther 9(3):156\u2013164. https:\/\/doi.org\/10.5582\/ddt.2015.01012","journal-title":"Drug Discov Ther"},{"issue":"6","key":"3788_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3967\/bes2015.066","volume":"28","author":"Q Li","year":"2015","unstructured":"Li Q, Dong HY, Pang Y et al (2015) Multicenter Evaluation of the Molecular Line Probe Assay for Multidrug Resistant Mycobacterium Tuberculosis Detection in China. Biomed Environ Sci 28(6):464\u2013467. https:\/\/doi.org\/10.3967\/bes2015.066","journal-title":"Biomed Environ Sci"},{"key":"3788_CR7","volume-title":"A Field Guide: A Companion Document to Guidelines for Programmatic Management of Drug-Resistant Tuberculosis","author":"Management of MDR-TB","year":"2009","unstructured":"Management of MDR-TB (2009) A Field Guide: A Companion Document to Guidelines for Programmatic Management of Drug-Resistant Tuberculosis. World Health Organization, Geneva"},{"issue":"3","key":"3788_CR8","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1183\/09031936.00073611","volume":"38","author":"D Falzon","year":"2011","unstructured":"Falzon D, Jaramillo E, Sch\u00fcnemann HJ et al (2011) WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 38(3):516\u2013528. https:\/\/doi.org\/10.1183\/09031936.00073611","journal-title":"Eur Respir J"},{"issue":"2","key":"3788_CR9","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1097\/01.mjt.0000433951.09030.5a","volume":"23","author":"S Wu","year":"2016","unstructured":"Wu S, Zhang Y, Sun F et al (2016) Adverse Events Associated With the Treatment of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis. Am J Ther 23(2):e521\u2013e530. https:\/\/doi.org\/10.1097\/01.mjt.0000433951.09030.5a","journal-title":"Am J Ther"},{"issue":"5707","key":"3788_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","volume":"307","author":"K Andries","year":"2005","unstructured":"Andries K, Verhasselt P, Guillemont J et al (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307(5707):223\u2013227. https:\/\/doi.org\/10.1126\/science.1106753","journal-title":"Science"},{"key":"3788_CR11","unstructured":"FDA. 2012. Anti-infective drugs advisory committee meeting: briefing document. TMC207 (bedaquiline) treatment of patients with MDR-TB: NDA 204\u2013384. FDA Silver Spring MD"},{"issue":"6","key":"3788_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nchembio884","volume":"3","author":"A Koul","year":"2007","unstructured":"Koul A, Dendouga N, Vergauwen K et al (2007) Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 3(6):323\u2013324. https:\/\/doi.org\/10.1038\/nchembio884","journal-title":"Nat Chem Biol"},{"issue":"5","key":"3788_CR13","doi-asserted-by":"publisher","first-page":"1800544","DOI":"10.1183\/13993003.00544-2018","volume":"1","author":"O Olayanju","year":"2018","unstructured":"Olayanju O, Limberis J, Esmail A et al (2018) Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. Eur Respir J 1(5):1800544. https:\/\/doi.org\/10.1183\/13993003.00544-2018","journal-title":"Eur Respir J"},{"issue":"1","key":"3788_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ddr.21498","volume":"80","author":"Y Li","year":"2019","unstructured":"Li Y, Sun F, Zhang W (2019) Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging. Drug Dev Res 80(1):98\u2013105. https:\/\/doi.org\/10.1002\/ddr.21498","journal-title":"Drug Dev Res"},{"key":"3788_CR15","unstructured":"WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization. 2019"},{"key":"3788_CR16","unstructured":"FDA Office of Antimicrobial Products Briefing package NDA 204\u2013384 SirturoTM (bedaquiline 100 mg tablets) for the treatment of adults (18 years) as part of combination therapy of pulmonary multi-drug resistant tuberculosis (MDRTB). Accessed 13 March 2014"},{"issue":"5","key":"3788_CR17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1124\/dmd.113.056119","volume":"42","author":"K Liu","year":"2014","unstructured":"Liu K, Li F, Lu J et al (2014) Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos 42(5):863\u2013866. https:\/\/doi.org\/10.1124\/dmd.113.056119","journal-title":"Drug Metab Dispos"},{"key":"3788_CR18","unstructured":"Janssen Therapeutics. 2021. Sirturo (bedaquiline) package insert FDA approved. Janssen Products Titusville NJ"},{"key":"3788_CR19","unstructured":"Mesens N, Verbeeck J, Rouan M. 2007. Elucidating the role of M2 in the preclinical safety profile of TMC207, abstr PS-71291\u201311. Proc. 38th World Conf. Lung Health Cape Town, South Africa."},{"key":"3788_CR20","unstructured":"Janssen Pharmaceutical Companies. 28 November 2012. Briefing document TMC207 (bedaquiline) treatment of patients with MDR-TB NDA 204 \u2013384. Janssen Pharmaceutical Companies Titusville NJ"},{"issue":"9","key":"3788_CR21","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1093\/jac\/dku171","volume":"69","author":"RP van Heeswijk","year":"2014","unstructured":"van Heeswijk RP, Dannemann B, Hoetelmans RM (2014) Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J Antimicrob Chemother 69(9):2310\u20132318. https:\/\/doi.org\/10.1093\/jac\/dku171","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"3788_CR22","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1313865","volume":"371","author":"AH Diacon","year":"2014","unstructured":"Diacon AH, Pym A, Grobusch MP et al (2014) Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 371(8):723\u2013732. https:\/\/doi.org\/10.1056\/NEJMoa1313865","journal-title":"N Engl J Med"},{"key":"3788_CR23","unstructured":"Janssen Pharmaceuticals Sirturo, United States product insert.com\/sites\/default\/files\/pdf\/sirturo-pi.pdf>. Accessed 13 March 2014"},{"key":"3788_CR24","doi-asserted-by":"publisher","unstructured":"Shamseer L, Moher D, Clarke M et al (2016) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation [published correction appears in BMJ. 2016 Jul 21;354:i4086].\u00a0BMJ 350:g7647. https:\/\/doi.org\/10.1136\/bmj.g7647","DOI":"10.1136\/bmj.g7647"},{"issue":"4","key":"3788_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","volume":"34","author":"MN Neely","year":"2012","unstructured":"Neely MN, van Guilder MG, Yamada WM et al (2012) Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 34(4):467\u2013476. https:\/\/doi.org\/10.1097\/FTD.0b013e31825c4ba6","journal-title":"Ther Drug Monit"},{"issue":"4","key":"3788_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2165\/00003088-200645040-00003","volume":"45","author":"A Bustad","year":"2006","unstructured":"Bustad A, Terziivanov D, Leary R et al (2006) Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet 45(4):365\u2013383. https:\/\/doi.org\/10.2165\/00003088-200645040-00003","journal-title":"Clin Pharmacokinet"},{"key":"3788_CR27","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","volume":"54","author":"S Kanji","year":"2015","unstructured":"Kanji S, Hayes M, Ling A et al (2015) Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement. Clin Pharmacokinet 54:783\u2013795","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"3788_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bcp.12233","volume":"79","author":"SB Duffull","year":"2015","unstructured":"Duffull SB, Wright DF (2015) What do we learn from repeated population analyses? Br J Clin Pharmacol 79(1):40\u201347","journal-title":"Br J Clin Pharmacol"},{"key":"3788_CR29","unstructured":"US Department of Health and Human Services. Statistical approaches to establishing bioequivalence. Rockville: US FDA, US Center for Drug Evaluation and Research 2001"},{"issue":"6","key":"3788_CR30","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1365-2125.2010.03891.x","volume":"71","author":"SB Duffull","year":"2011","unstructured":"Duffull SB, Wright DF, Winter HR (2011) Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint. Br J Clin Pharmacol 71(6):807\u2013814. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03891.x","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"3788_CR31","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1128\/AAC.01418-13","volume":"58","author":"SC McLeay","year":"2014","unstructured":"McLeay SC, Vis P, van Heeswijk RP et al (2014) Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug. Antimicrob Agents Chemother 58(9):5315\u20135324. https:\/\/doi.org\/10.1128\/AAC.01418-13","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"3788_CR32","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1128\/AAC.00191-13","volume":"57","author":"EM Svensson","year":"2013","unstructured":"Svensson EM, Aweeka F, Park JG et al (2013) Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother 57(6):2780\u20132787. https:\/\/doi.org\/10.1128\/AAC.00191-13","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"3788_CR33","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/psp4.12147","volume":"5","author":"EM Svensson","year":"2016","unstructured":"Svensson EM, Dosne AG, Karlsson MO (2016) Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin. CPT Pharmacometrics Syst Pharmacol 5(12):682\u2013691. https:\/\/doi.org\/10.1002\/psp4.12147","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"3788_CR34","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1093\/jac\/dku504","volume":"70","author":"EM Svensson","year":"2015","unstructured":"Svensson EM, Murray S, Karlsson MO et al (2015) Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother 70(4):1106\u20131114. https:\/\/doi.org\/10.1093\/jac\/dku504","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"3788_CR35","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/jcph.1887","volume":"61","author":"K Kurosawa","year":"2021","unstructured":"Kurosawa K, Rossenu S, Biewenga J et al (2021) Population Pharmacokinetic Analysis of Bedaquiline-Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized. Pharmacokinetic Study J Clin Pharmacol 61(10):1344\u20131355. https:\/\/doi.org\/10.1002\/jcph.1887","journal-title":"Pharmacokinetic Study J Clin Pharmacol"},{"issue":"12","key":"3788_CR36","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.5588\/ijtld.21.0158","volume":"25","author":"H Zhu","year":"2021","unstructured":"Zhu H, Xie L, Liu ZQ et al (2021) Population pharmacokinetics of bedaquiline in patients with drug-resistant TB. Int J Tuberc Lung Dis 25(12):1006\u20131012. https:\/\/doi.org\/10.5588\/ijtld.21.0158","journal-title":"Int J Tuberc Lung Dis"},{"key":"3788_CR37","doi-asserted-by":"publisher","first-page":"1022090","DOI":"10.3389\/fphar.2023.1022090","volume":"14","author":"G Shao","year":"2023","unstructured":"Shao G, Bao Z, Davies Forsman L et al (2023) Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients. Front Pharmacol 14:1022090. https:\/\/doi.org\/10.3389\/fphar.2023.1022090","journal-title":"Front Pharmacol"},{"issue":"10","key":"3788_CR38","doi-asserted-by":"publisher","first-page":"e0081122","DOI":"10.1128\/aac.00811-22","volume":"66","author":"J Zou","year":"2022","unstructured":"Zou J, Chen S, Rao W et al (2022) Population Pharmacokinetic Modeling of Bedaquiline among Multidrug-Resistant Pulmonary Tuberculosis Patients from China. Antimicrob Agents Chemother 66(10):e0081122. https:\/\/doi.org\/10.1128\/aac.00811-22","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"3788_CR39","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1093\/cid\/ciac252","volume":"75","author":"JA Hughes","year":"2022","unstructured":"Hughes JA, Solans BP, Draper HR et al (2022) Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis. Clin Infect Dis 75(10):1772\u20131780. https:\/\/doi.org\/10.1093\/cid\/ciac252","journal-title":"Clin Infect Dis"},{"key":"3788_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2133\/dmpk.24.25","volume":"24","author":"BJ Anderson","year":"2009","unstructured":"Anderson BJ, Holford Nick HG (2009) Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 24:25\u201336","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"3788_CR41","doi-asserted-by":"publisher","first-page":"202","DOI":"10.7883\/yoken.JJID.2008.202","volume":"61","author":"K Ramakrishnan","year":"2008","unstructured":"Ramakrishnan K, Shenbagarathai R, Kavitha K et al (2008) Serum zinc and albumin levels in pulmonary tuberculosis patients with and without HIV. Jpn J Infect Dis 61(3):202\u2013204","journal-title":"Jpn J Infect Dis"},{"issue":"11","key":"3788_CR42","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1590\/s1806-37132008001100009","volume":"34","author":"E Peresi","year":"2008","unstructured":"Peresi E, Silva SM, Calvi SA et al (2008) Cytokines and acute phase serum proteins as markers of inflammatory regression during the treatment of pulmonary tuberculosis. J Bras Pneumol 34(11):942\u2013949. https:\/\/doi.org\/10.1590\/s1806-37132008001100009","journal-title":"J Bras Pneumol"},{"issue":"5","key":"3788_CR43","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1056\/NEJM199502023320518","volume":"332","author":"KB Patel","year":"1995","unstructured":"Patel KB, Belmonte R, Crowe HM (1995) Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med 332(5):336\u2013337. https:\/\/doi.org\/10.1056\/NEJM199502023320518","journal-title":"N Engl J Med"},{"issue":"9","key":"3788_CR44","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1177\/106002809603000901","volume":"30","author":"CA Peloquin","year":"1996","unstructured":"Peloquin CA, Nitta AT, Burman WJ et al (1996) Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 30(9):919\u2013925. https:\/\/doi.org\/10.1177\/106002809603000901","journal-title":"Ann Pharmacother"},{"issue":"4","key":"3788_CR45","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/0003-4819-127-4-199708150-00006","volume":"127","author":"J Sahai","year":"1997","unstructured":"Sahai J, Gallicano K, Swick L et al (1997) Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 127(4):289\u2013293. https:\/\/doi.org\/10.7326\/0003-4819-127-4-199708150-00006","journal-title":"Ann Intern Med"},{"issue":"9","key":"3788_CR46","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","volume":"42","author":"M Niemi","year":"2003","unstructured":"Niemi M, Backman JT, Fromm MF et al (2003) Pharmacokinetic interactions with rifampicin\u202f: clinical relevance. Clin Pharmacokinet 42(9):819\u2013850. https:\/\/doi.org\/10.2165\/00003088-200342090-00003","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"3788_CR47","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/s0169-409x(02)00066-2","volume":"54","author":"JK Lamba","year":"2002","unstructured":"Lamba JK, Lin YS, Schuetz EG et al (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54(10):1271\u20131294. https:\/\/doi.org\/10.1016\/s0169-409x(02)00066-2","journal-title":"Adv Drug Deliv Rev"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03788-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03788-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03788-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T07:12:17Z","timestamp":1739430737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03788-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3788"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03788-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"31 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}